|Title||Professor and Director for Tumor Biotherapy|
Dr. Limin Zheng is the Director for Tumor Biotherapy, Cancer Center. He graduated from Shanghai Medical University and then worked as physician in Hua-Shan Hospital. He obtained his PhD in Immunology from Leiden University, The Netherlands in 1994 and was promoted as Assistant Professor by Swedish Medical Research Council in 1998. Since 2003, he is full Professor at Sun Yat-Sen University. He received the Outstanding Young Scientist Fund from National Natural Science Fund of China in 2004 and the honors as Cheung Kong Scholars by Ministry of Education in 2009. Specialty & Research Field of Interests:
Macrophage (Mφ) immunobiology, tumor molecular staging & tumor-immune therapy. Mφ constitute a major component of the leukocyte infiltrate in tumor stroma and markedly outnumber other APC. By paying particular attention to the tissue micro-localization, we investigated how human tumors dynamically educated the infiltrating immune cells and their clinical significance, with a focus on Mφ and hepatocellular carcinoma. Those studies will give important new insights into the “Immune-editing” in human tumors which represent the outcome of long-time co-evolution between cancer cells and host, and thus should be helpful for the rational design of effective immune-based anticancer therapies for patients.
For information on Professor Zheng's laboratory, click here and select: Influences of tumor microenvironments on infiltrating immune cells.
1979 - 1984 MD. Shanghai Medical University (SMU), Shanghai
1984 - 1990 Resident, Hua-Shan Hospital, SMU, Shanghai
1990 - 1994 PhD, Leiden University, The Netherlands
1994 - 1998 Post-Doctor, Lund and Linkoping University, Sweden
1999 - 2002 Assistant Prof. at Linkoping University, Sweden
2003 - present Prof. at SunYat-sen University (SYSU), Guangzhou
2007 - present Prof. & Director for Tumor Biotherapy; Cancer Center, SYSU
1. DM Kuang, X Xiao, Q Zhao, MM Chen, XF Li, RX Liu, Y Wei, FZ Ouyang, DP Chen, Y Wu, XM Lao, H Deng, and L Zheng. B7-H1-expressing antigen-presenting cells mediate polarization of pro-tumorigenic Th22 subset. J. Clin. Invest. 2014, in press.
2. XF Li, DP Chen, FZ Ouyang, MM Chen, Y Wu, DM Kuang, and L Zheng. Increased autophagy sustains the survival and protumorigenic effects of neutrophils in human cancers. J. Hepatol. 2014, in press
3. WC Wu, HW Sun, HT Chen, J Liang, XJ Yu, C Wu, Z Wang, L Zheng. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc. Natl. Acad. Sci. USA. 2014, 111: 4221–6.
4. J Hou, Y Zhou, Y Zheng, J Fan, W Zhou, IO Ng, H Sun, L Qin, S Qiu, JM Lee, CM Lo, K Man, Y Yang, Y Yang, Y Yang, Q Zhang, X Zhu, N Li, Z Wang, G Ding, SM Zhuang, L Zheng, X Luo, Y Xie, A Liang, Z Wang, M Zhang, Q Xia, T Liang, Y Yu, X Cao. Hepatic RIG-I predicts survival and Interferon-α therapeutic response in Hepatocellular carcinoma. Cancer Cell. 2014; 25:49-63.
5. Y Wu, DM Kuang, WD Pan, YL Wan, XM Lao, D Wang, XF Li, L Zheng. Monocyte /Macrophage-elicited NK cell dysfunction in Hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology, 2013; 57:1107-16.
6. J Yan, Y Zhang, JP Zhang, J Liang, L Li, L Zheng. Tim-3 expression defines regulatory T cells in human tumors. PLoS ONE, 2013; 8: e58006.
7. J Xu, T Ding, Q He, X Yu, W Wu, W Jia, J Yun, Y Zhang, M Shi, C Shao, WD Pan, X Yin, J Min, SM Zhuang, L Zheng. In Situ molecular signature predict early recurrence in Hepatitis B virus-related hepatocellular carcinoma. J. Hepatol. 2012; 57: 313-21.
8. Q Zhao, DM Kuang, Y Wu, X Xiao, X Li, T Li, L Zheng. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J. Immunol. 2012; 188:1117-24.
9. DM Kuang, Q Zhao, Y Wu, C Peng, J Wang, Z Xu, XY Yin, and L Zheng. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J. Hepatol. 2011, 54:948–55.
10. T Ding, J Xu, Y Zhang, R Guo, W Wu, S Zhang, CN Qian, and L Zheng. Endothelium coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer. 2011, 117:4878-89.
11. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011, 19:232-43.
12. DM Kuang, C Peng, Q Zhao, Y Wu, LY Zhu, J Wang, XY Yin, and L Zheng. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J. Immunol. 2010, 185:1544-9.
13. DM Kuang, C Peng, Q Zhao, Y Wu, MS Chen, and L Zheng. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory Th17 cells. Hepatology. 2010, 51:154-64.
14. JP Zhang, J Yan, J Xu, XH Pang, MS Chen, L Li, C Wu, SP Li, and L Zheng. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50:980-9.
15. DM Kuang, QY Zhao, C Peng, J Xu, JP Zhang, C Wu, and L Zheng. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009, 206: 1327-37.
16. T Ding, J Xu, F Wang, M Shi, Y Zhang, SP Li, and L Zheng. High tumor infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma following resection. Human Pathol, 2009, 40:381-9.
17. J Zhou, T Ding, LY Zhu, W Pan, L Li, and L Zheng. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int. J. Cancer. 2009, 125:1640-8.
18. DM Kuang, Q Zhao, J Xu, JP Yun, C Wu, and L Zheng. Tumor-educated tolerogenic dendritic cells induce CD3ε down-regulation and apoptosis of T cells through oxygen-dependent pathways. J. Immunol. 2008, 181:3089-98.
19. J Cheng, DH Huo, DM Kuang, J Yang, L Zheng*, and SM Zhuang*. Human macrophage promotes the motility and invasiveness of Osteopontin-knockdown tumor cells. Cancer Res. 2007, 67: 5141–7. (* co-corresponding authors)
20. DM Kuang, Y Wu, N Chen, J Cheng, SM Zhuang, and L Zheng. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007, 110:587-95.
Last updated on: September, 2014
|Title||Professor and Director|
Dr. Jianchuan Xia is professor and director of cell therapy and healthcare research Center. Dr. Xia obtained his PhD at Harbin University of Medical Sciences, P. R. China in 1998. His postdoctoral training at Harvard University provided him with great opportunities to explore the fields of tumor immune therapy and tumorigenesis. He then rejoined the Department of Biotherapy at Sun Yat-sen University Cancer Center (SYSUCC) as a Professor in 2003. In 2013, Dr. Xia was appointed Director of Department of Cell therapy and Healthcare Research Center. Dr. Xia has published more than 80 research papers.
(1) Cancer genetics study: Tumor suppressor gene down-regulation may play an important role in tumor progress and development. We investigated several tumor suppressors such as ING2, TESTIN, BATF2, LZAP and BIN1, et al. expression in primary hepatocellular carcinoma (HCC) or gastric cancer (GC) and evaluated the relationship between these tumor suppressors’ expression and clinicopathological parameters of HCC or GC. Meanwhile, the prognostic value of these tumor suppressors for HCC or GC patients was also investigated. Furthermore, by examining in vitro proliferation, clone formation, motility, invasion and apoptosis of tumor cell lines, he also study the functional role of these tumor suppressors in the tumorigenesis of HCC or GC.
(2) Cancer Immunotherapy study: Immunotherapy is an important comprehensive treatment method for cancer patient. In Dr. Xia’s group, heinvestigated several immuno-effector cells such as cytokines induced killer cells (CIK), natural killer cells (NK), dendritic cells (DC) and DC-CIK for treatment of cancer patients. Furthermore, he investigated negative regulator such as SOCS1 and IDO for the function of DC, and studied whether silencing these negative regulators could enhance the anti-tumor immunity of DC. More ever, he also investigated that DC/tumor fusion vaccines or genetic modified-DC vaccines for the treatment of cancer patients.For information on Professor Xia's laboratory, click here and select: Gene function and regulation.
1980-1984 B.S. Biology, Nanchang University, Jiangxi, P.R. China.
1991-1994 M.S. Cancer genetics, Harbin Medical Univercity, Haerbin, P.R.China.
1994-1997 Ph.D. Cancer genetics, Harbin Medical Univercity, Haerbin, P.R.China.
1998-2000 Postdoctoral. Cancer genetics, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
2000-2003 Postdoctoral. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
1. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP, Xia JC (Corresponding). The Accumulation and Prognosis Value of Tumor Infiltrating IL-17 Producing Cells in Esophageal Squamous Cell Carcinoma. PLoS One. 2011 Mar 31;6(3):e18219
2. Liang XT, Pan K, Chen MS, Li JJ, Wang H, Zhao JJ, Sun JC, Chen YB, Ma HQ, Wang QJ, Xia JC (Corresponding). Decreased expression of XPO4 is associated with poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011 Mar;26(3):544-9.
3. Ma H, Liang X, Chen Y, Pan K, Sun J, Wang H, Wang Q, Li Y, Zhao J, Li J, Chen M, Xia J (Corresponding). Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer. 2011 Feb 15;128(4):771-7.
4. Ma H, Weng D, Chen Y, Huang W, Pan K, Wang H, Sun J, Wang Q, Zhou Z, Wang H, Xia J (Corresponding). Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene. Mol Cancer. 2010 Jul 13;9:190.
5. Chen JG, Xia JC (Corresponding), Liang XT, Pan K, Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB, Ma HQ, Zeng ZW, Zhou ZW, Chang AE, Li Q. Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients. Int J Biol Sci. 2011 Jan 11;7(1):53-60.
6. Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC, Chen YB, Ma HQ, Liu Q, Xia JC (Corresponding). Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate. Int J Biol Sci. 2010 Oct 13;6(7):639-48.
7. Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB, Xia JC (Corresponding). High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World J Gastroenterol. 2010 Sep 28;16(36):4611-5.
8. Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, He J, Ke ML, Zhao JJ, Li JJ, Sun JC, Liang XT, Ma HQ, Chen YB, Xia JC (Corresponding). Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer. 2010 Jul;29(7):641-8.
9. Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, Li YQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL, Cao Y, Guan XY, Lian QZ, Xia JC (Corresponding). Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010 Aug;10(4):368-75.
10. Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J (Corresponding). Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010 Jun 6;9(11).
11. Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, Zhou J, Li Y, Sun J, Chen Y, Liang X, Zhao J, Pan K, Wang H, Xia J (Corresponding). Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array. Oncol Rep. 2010 Feb;23(2):445-55.
12. Ma HQ, Liang XT, Zhao JJ, Wang H, Sun JC, Chen YB, Pan K, Xia JC (Corresponding). Decreased expression of Neurensin-2 correlates with poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2009 Oct 14;15(38):4844-8.
13. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia JC (Corresponding). Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunology Immunotherapy, 2009 Oct;58(10):1587-97.
14. Pan K, Wang H, Liu W, Zhang H, Zhou J, Li J, Weng D, Huang W, Sun J, Liang X, Xia JC (Corresponding). The pivotal role of p38 and NF-κB signal pathways in the maturation of human monocyte-derived dendritic cells stimulated by streptococcal agent OK-432. Immunobiology, 2009, 214(5):350-358.
15. Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC (Corresponding). Decreased Expression of Ing2 Gene and Its Clinicopathological Significance in Hepatocellular Carcinoma. Cancer Lett, 2008, 261(2): 183-192.
16. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH, Xia JC (Corresponding). Minimally Invasive Treatment Combined with Cytokine-Induced Killer Cells Therapy Lower the Short-Term Recurrence Rates of Hepatocellular Carcinomas. J Immunother, 2008, 31(1): 63-71.
17. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC (Corresponding). Increased Polycomb-Group Oncogene Bmi-1 Expression Correlates with Poor Prognosis in Hepatocellular Carcinoma. J Cancer Res Clin Oncol. 2008, 134(5): 535-541.
18. Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC (Corresponding). Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008, 134(11):1247-1253
19. Li JJ, Xu GL, Gu MF, Luo GY, Rong Z, Wu PH, Xia JC (corresponding). Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors. World J Gastroenterol. 2007, 13(19):2747-2751.
20. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother. 2007, 56(10):1597-1604.
21. Weng DS, Li JT, Mai SJ, Pan ZZ, Feng BJ, Feng QS, Huang LX, Wang QJ, Li YQ, Yu XJ, Chen SP, He J, Xia JC (corresponding). Identification of a new target region on the long arm of chromosome 7 in gastric carcinoma by loss of heterozygosity. World J Gastroenterol. 2006, 12(15):2437-2440.
22. Xia JC, Weng DS, Li JT, Qin HD, Mai SJ, Feng BJ, Fan Q, Feng QS, Huang LX, Yu XJ, Pan ZZ, Li YQ, Wang QJ, Zhan YQ, Chen SP, He J, Huang WL, Wu PH, Zeng YX. Loss of heterozygosity analysis of a candidate gastric carcinoma tumor suppressor locus at 7q31. Cancer Genet Cytogenet. 2006, 166(2):166-172.
23. Liu JY, Zhang XS, Ding Y, Peng RQ, Cheng X, Zhang NH, Xia JC, Zeng YX. The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. J Transl Med. 2005, 28;3(1):5.
24. Zhang XS, Wang HH, Hu LF, Li A, Zhang RH, Mai HQ, Xia JC, Chen LZ, Zeng YX. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett. 2004, 211(1):11-18
25. Tanaka Y, Koido S, Xia JC, Ohana M, Liu C, Cote GM, Sawyer DB, Calderwood S, Gong J. Development of Antigen-Specific CD8+ Cytotoxic T Lymphocytes in MHC Class I-Deficient Mice through CD4 to CD8 Conversion. J Immunol, 2004, 172: 7848-7858.
26. Xia JC, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol, 2003, 170 (4):1980-1986.
27. Chen D, Xia JC, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cell and mucin 1-positive carcinoma cells. Immunology 2003, 109:300-307.
28. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P, Feng QS, Huang LX, Yu XJ, Li D, Chen LZ, Jia WH, Fang Y, Huang HM, Zhu JL, Liu XM, Zhao Y, Liu WQ, Deng MQ, Hu WH, Wu SX, Mo HY, Hong MF, King MC, Chen Z, Zeng YX. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. 2002, 31(4):395-399
29. Zhang XS, Song KH, Mai HQ, Jia WH, Feng BJ, Xia JC, Zhang RH, Huang LX, Yu XJ, Feng QS, Huang P, Chen JJ, Zeng YX. The 30-bp deletion variant: a polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer Lett. 2002, 176(1):65-73
Last updated on: 2011
|Title||Professor, Vice Director of Tumor Biotherapy Department|
1. Comprehensive treatment of melanoma
2. Immunotherapy of Liver cancer, colon cancer, lung cancer, breast cancer and other kinds of tumors
1988 – 1995 Attending Physician, The First Affiliated Hospital of Chongqing Medical University
1995 – 1998 Associate Professor, The First Affiliated Hospital of Chongqing Medical University
2000 – Present Professor & Vice Director of Tumor Biotherapy Department, Sun Yat-Sen University Cancer Center
1979 – 1983 MB, Chongqing Medical University
1983 – 1988 MM, The First Affiliated Hospital of Chongqing Medical University
1995 – 1998 PhD, Chongqing Medical University
1998 – 2000 Post-Doctor, Sun Yat-Sen University Cancer Center
August – October, 2005 Visiting Scholar, Karolinska University, Sweden
Last updated on: May, 2014
Dr. Xing Zhang is professor of Department of Biotherapy. Dr. Zhang obtained her Bachelor in Clinical Medicine (equivalent to MD in the US) at Henan Medical University and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1994 and 2004, respectively. Her postdoctoral training at Pulmonary Center of Boston University provided her with great opportunities to explore the fields of tumorigenesis, new targeted therapy and signal transduction. Dr. Zhang has published more than 30 research papers. Her specialties are tumor biotherapy and targeted therapy, especially for malignant melanoma, kidney cancer, soft tissue sarcoma, lung cancer and liver cancer.
|Phone||020 87343629 020 87343383|
|Research Interest(s)||New targeted therapy, Immunotherapy and Signal transduction|
|Education||M.D. and PhD|
1. Kuang BH, Zhang MQ, Xu LH, Hu LJ, Wang HB, Zhao WF, Du Y, Zhang X *. Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival. Br J Cancer. 2013 Sep 3;109(5):1252-63
2. Kuang BH, Wen XZ, Ding Y, Peng RQ, Cai PQ, Zhang MQ, Jiang F, Zhang XS, Zhang X *. The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients. Med Oncol. 2013 Jun;30(2):536.
3. Zhao WF, Wang HB, Xie B, Hu LJ, Xu LH, Kuang BH, Li MZ, Zhang X *. Sp1 and Sp3 are involved in the full transcriptional activity of centromere protein H in human nasopharyngeal carcinoma cells. FEBS J. 2012 Aug; 279(15):2714-26.
4. Zhang X, Xu LH, Yu Q. Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth. Mol Cancer 2010 Jan 14;9(1):7.
5. Zhang X, Wang B, Zhang XS, Li ZM, Guan ZZ, Jiang WQ. Serum diagnosis of diffuse large B-cell lymphomas and further identification of response to therapy using SELDI-TOF-MS and tree analysis patterning. BMC Cancer 2007; Dec 29;7:235.
6. Zhang X, Wei L, Yang Y, Yu Q. Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J Cell Biochem 2004; 93(4):819-829.
7. Zhou QM, Li W, Zhang X, Chen YB, Chen XC, Guan YX, Ding Y, Wen XZ, Xia Q, Zhou Q, Peng RQ, Hou JH, Zhu XF, Zeng YX, Zhang XS. The mutation profiles of common oncogenes involved in melanoma in southern China. J Invest Dermatol. 2012 Jul;132(7):1935-7.
8. He YF, Wei W, Zhang X, Li YH, Li S, Wang FH, Lin XB, Li ZM, Zhang DS, Huang HQ, Hu B, Jiang WQ Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther. 2008 Jun;33(3):307-1
9. Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS. CENP-H is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival. Clin Cancer Res, 2007; 13(2):508-14.
10. Qin L, Zhang X, Zhang L, Feng Y, Weng GX, Li MZ, Kong QL, Qian CN, Zeng YX, Zeng MS, Liao DF, Song LB. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2008 Jul 4;371(3):531-5.
11. Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS, Huang KH. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 2008; 97(3):267-72.
12. Wei L, Yang Y, Zhang X, Yu Q. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004; 23(56): 9052-61.
|Title||Doctor of Medicine and associate chief physician|
After she got a bachelor's degree in medicine in former Sun Yat-sen University of Medical Sciences in 2011, Dr. Peng started to work in the Biotherapy Research Center in Cancer Center. In the same year, she incepted a doctorate in oncology. In 2013, she was promoted to associate chief physican. She mainly focuses on the biotherapy of malignant cander, melanin medical treatment and is familiar with the medical treatment of all sorts of solid tumors.
1. Peng RQ, et al. A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma. Cancer Biol Ther. 2012.12.
2. Peng RQ, et al. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.BMC Cancer. 2010;10:496.
3. Peng RQ, et al. Expression of calreticulin is associated with the infiltration of T-cells in stage IIIB colon cancer.World J Gastroenterol.2010；16（19）2428-2434.
4. Gao YF, Peng RQ, et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med. 2009;7:71
|Title||Professor and Doctoral Supervisor|
In 1992 Prof. Li graduated from Department of Medicine, Chongqin Medical University and in 2002 she graduated from former Sun Yat-sen University of Medical Sciences as a doctor with PhD. In 2004, she engaged in short-term advanced studies in the Microorganisms and Oncotherapy Center in Karolinska Institutet in Sweden. From 2008 to 2010, she participated in advanced studies in Cell and Gene Therapy Center in Baylor University in USA. Currently she serves as a professor in Sun Yat-sen University Cancer Center and she is also the doctoral supervisor in the Biotherapy Center.
EBV-LMP1 induced the differentiation and functional imbalance of cancer associated immune cells through up-regulation of Warburg effect of nasopharyngeal carcinoma
China National Nature Foundation (81372442，Jiang Li.) 1/1/2014 – 12/31/2018
China National Nature Foundation (81172164，Jiang Li.) 1/1/2012 – 12/31/2015
She studies on the mechanism of immunotherapy of malignant cancer and T lymphocytes, as well as the imunne escape of malignant cander. Antigen specific T lymphocytes immunotherapy is a new development direction of clinical treatment, featuring targeting and safety. The immunological environment formed by a large number of infiltrating lymphocytes around various malignant tumor issue bears a great importance for the immune escape and immunotherapy, in which the CD4 lymphocyte subset influenced the function of CD8+ effector T cells strongly. See mainly researches on T lymphocytes' monitor, therapeutic action and regulatory mechanism of malignant cancer.
Li J#, Chen QY#, He J, Li ZL, Tang XF, Chen SP, Xie CM, Li YQ, Huang LX, Ye SB, Ke ML, Tang LQ, Liu H, Zhang L, Guo SS, Xia JC, Zhang XS, Zheng LM, Guo X, Qian CN, Mai HQ*, Zeng YX*.Phase I Trial of Adoptively Transferred Tumor-infiltrating Lymphocyte Immunotherapy Following ConcurrentChemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Oncoimmunology. 2015.Mar 6; 2(4):e976507. (IF = 6.26)
.Ye SB, Li ZL, Luo DH, Huang BJ, Chen YS, Zhang XS, Cui J, ZengYX,Li J*.Tumor-derived exosomes promote tumor progression and T-cell dysfunction throughthe regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014 Jul 30;5(14):5439-52.(IF = 6.67)（Correspondence）
. OuYang LY#, Wu XJ#, Ye SB, Zhang RX, Li ZL, Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z, Li Q, Ma G*, Li J*. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. JTransl Med. 2015 Feb 1;13(1):47. (IF = 3.99) （Correspondence）
. Zhang L#, Ye SB#, Li ZL, Ma G, Chen SP, He J, Liu WL, Xie D, Zeng YX, Li J*.Increased HIF-1alpha expression in tumor cells and lymphocytes of tumormicroenvironments predicts unfavorable survival in esophageal squamous cellcarcinoma patients. Int J ClinExpPathol. 2014 Jun 15;7(7):3887-97.(IF = 1.78) （Correspondence）
. Zhang L#, Ye SB#, Ma G, Tang XF, Chen SP, He J, Liu WL, Xie D, Zeng YX, Li J*.The expressions of MIF and CXCR4 protein in tumor microenvironment are adverseprognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 2013 Mar 8;11:60.(IF = 3.99) （Correspondence）
.Li J#*, Mo HY#, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM, Qian CN*, Zeng YX. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem. 2012 Oct 12;287(42):35484-95. (Correspondence）(IF=4.67)
. He J, Tang XF, Chen QY, Mai HQ, Huang ZF, Li J*, Zeng YX. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer. 2012 Jun;31(6):287-94.（Correspondence）
.Li J*, Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ, Chen QY, He J, Chen SP, Zheng LM, Qian CN, Zeng YX. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.JTransl Med. 2011 Nov 4;9(1):189. （Correspondence）(SCI, IF=3.4740(2011))
. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, Xia Y, Jiang WQ, Zeng YX*, Li J*. Circulating and Tumor-Infiltrating Foxp3 Regulatory T Cell Subset in Chinese Patients with Extranodal NK/T Cell Lymphoma. Int J Biol Sci. 2011;7(7):1027-36. （Correspondence）(SCI, IF=4.3)
.Li J#, Chen QY#, Mo H, Zhang YL, Huang ZF, Zeng YX*. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy. Int J Biol Sci. 2011;7(5):607-17. (IF=4.3)
. Zhang YL#, Li J#（Co-first author）, Mo HY, Qiu F, Zheng LM, Qian CN, Zeng YX*. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer. 2010 Jan 10; 9: 4. (IF=5.3)
Dr. Desheng Weng is associate professor of cell therapy and healthcare research Center. Dr. Weng obtained his Bachelor in Medicine (equivalent to MD in the US) at First Military Medical University and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1998 and 2005, respectively. His postdoctoral training at Boston University Medical School provided him with great opportunities to explore the fields of tumor immune therapy and tumorigenesis. He then joined the Department of Cell therapy and Healthcare Research Center and Department of Biotherapy at Sun Yat-sen University Cancer Center (SYSUCC) as associate professor in 2012. Dr. Weng has published more than 20 research papers.
(1) Cancer genetics studyTumor suppressor gene down-regulation may play an important role in tumor progress and development. We investigated several tumor suppressors such as ING2, TESTIN, BATF2, LZAP and BIN1, et al. expression in primary hepatocellular carcinoma (HCC) or gastric cancer (GC) and evaluated the relationship between these tumor suppressors’ expression and clinicopathological parameters of HCC or GC. Furthermore, by examining in vitro proliferation, clone formation, motility, invasion and apoptosis of tumor cell lines, we also study the functional role of these tumor suppressors in the tumorigenesis of HCC or GC.
(2) Cancer Immunotherapy studyImmunotherapy is an important comprehensive treatment method for cancer patient. Dr. Weng investigated several immuno-effector cells such as cytokines induced killer cells (CIK), natural killer cells (NK), dendritic cells (DC) and DC-CIK for treatment of cancer patients. More ever, he also investigated that DC/tumor fusion vaccines or genetic modified-DC vaccines for the treatment of cancer patients.
1993-1998 M.D. Medicine, First Military Medical University, Guangzhou, P.R. China.
2001-2004 M.S. Pathology, First Military Medical University, Guangzhou, P.R. China.
2005-2008 Ph.D. Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
2008-2012 Postdoctor. Boston University Medical School, Boston, US.
1. Wu Z*, Weng D(co-first), Li G. Quantitative proteome analysis of overexpressed Cripto-1 tumor cell reveals 14-3-3gamma as a novel biomarker in nasopharyngeal carcinoma. J Proteomics, 83C: 26-36, 2013
2. Weng D, Song B, Koido S, Calderwood SK, Gong J*. Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation. J Immunol, 191(2): 755-763, 2013
3. Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J*. Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. Breast Cancer Res., 14(1):R18, 2012
4. Weng D, Calderwood SK, Gong J*. Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells. Methods Mol Biol.,787:255-65, 2011
5. Weng D, Song B, Durfee J, Sugiyama V, Wu Z, Koido S, Calderwood SK, Gong J*. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer., 129(8):1990-2001, 2011
6. Weng D, Cunin MC, Song B, Price BD, Eller MS, Gilchrest BA, Calderwood SK, Gong J*. Radiosensitization of mammary carcinoma cells by telomere homolog oligonucleotide pretreatment. Breast Cancer Res., 12(5):R71, 2010
7. Pan K, Wang Q, Liu Q, Zheng H, Li Y, Weng D, Li J, Huang L, He J, Chen S, Ke M, Zeng Y, Xia J*. The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Tumour Biol, 35(1): 701-707, 2014
8. Xia, JC*，Weng D. Progress of biotherapy in gastrointestinal carcinomas. Zhonghua Wei Chang Wai Ke Za Zhi 16(1): 22-27, 2013
9. Pan K, Zheng H, Zhao J, Pan Q, Li J, Weng D, Jiang S, Chang AE, Li Q*, Xia J*. OK-432 synergizes with IFN-γ to confer dendritic cells with sustained immunity and activate the p38 and NF-κB pathways. Immunology and Cell Biology, (Epub ahead of print), 2013
10. Lu L, Pan K, Zheng H, Li J, Qiu H, Zhao J, Weng D, Pan Q, Wang D, Jiang S, Chang AE, Li Q*, Xia J*. IL-17A promotes immune effector cell recruitment in human esophageal cancer by inducing tumor cell chemokine production , J Immunotherapy, 36: 451–458, 2013
11. Pan, QZ, Pan K, Weng D, Zhao J, Zhang X, Wang D, Lv L, Jiang S, Zheng H, Xia J*. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog, (Epub ahead of print), 2013
Last updated on: 2013
|Title||Master of Medicine, and attending physician|
Obtained a master degree in the Department of Clinical Medicine in Sun Yat-sen University in June, 2003, she serves as a resident physician in the biotherapy endemic area in the Cancer Center of Sun Yat-sen University. Since the end of 2005, she has served as the attending physician of this endemic area. She has studied Oncology for a doctor's degree since September, 2008. She is a master of melanoma treatment and is familiar with the medical treatment of all sorts of cancers, especially the biotherapy of cancer.
09/2005-06/2010 Sun Yat-sen University Cancer Center, Supervised by Professor Zhu Xiaofeng.
09/2000-06/2005 Graduated from the North Compus of Sun Yat-sen University and was conferred upon a Bachelor's degree.
09/2010-07/2012 Sun Yat-sen University Cancer Center, post-doctor with Professor Zhang Xiaoshi as a cooperation supervisor